Clinical study - patient info

The ImmUniverse clinical study

ImmUniverse wants to improve the quality of life for people living with atopic dermatitis and ulcerative colitis and ultimately those with other immune-mediated inflammatory diseases. This shall be achieved through a more personalised treatment tailored to the individual patient.

To this end, ImmUniverse conducts a clinical study at different sites across Europe for which we require patients with atopic dermatitis and ulcerative colitis willing to participate.

Are you interested in taking part? For more information about the study and how to take part, please read below.

  • Who are the people behind ImmUniverse?

    Clinicians and drug developers, basic immunologists, bioinformaticians as well as biotechnology and clinical development experts from several European universities, pharmaceutical companies and three European patient organisations (see below for details) joined forces in ImmUniverse. The project is funded by the Innovative Medicines Initiative (IMI JU), a partnership between the European Union and the European pharmaceutical industry. For you as a patient that also means that this project fosters the collaborative work of research and healthcare communities across different diseases like atopic dermatitis and ulcerative colitis.

  • Is there a possibility for me to participate – and if so, what would be the direct benefits for me?

    Naturally, you can participate. We are specifically looking for patients with moderate or severe disease symptoms and planned biological treatment. If you participate, you will benefit by receiving very close monitoring by experts in the field and you will get access to the most recent treatment developments. Also, participants will receive the latest news and have the chance to get in touch not only with experts but also with other patients facing similar problems which may help you in your daily routine.

  • I want to participate, what do I have to do?

    Simply get in touch with one of the recruitment centers, where you would be enrolled for regular treatment and monitoring for up to two years for each drug. That would include answering questionnaires in the waiting room and donating blood, tissue and stool samples (so called biomaterials) at multiple time points, when you are having your regular appointments. These regular appointments will not be prolonged by these study procedures. The recruitment centers are Kiel, Aarhus, Munich and Nijmegen for atopic dermatitis and Leuven, Amsterdam, Kiel, Nancy and Cambridge for ulcerative colitis.

  • Do I have to pay for participating?

    No, the costs are covered by ImmUniverse, which is funded by the IMI JU. However, please note that no travel costs to the centres are reimbursed.

  • If you work with my data – is that really safe?

    The European Union is very strict when it comes to data safety, so is ImmUniverse. No personal data and no data that can be tracked back to an individual will be shared or published. Everything is anonymised – so even if data were visible, nobody would ever see your name or be able to connect this data with you in any way. As an example, please find work from participating centres within ImmUniverse here. At any time of the study and even afterwards, you can quit the trial and ask for your data to be deleted. However, once these anonymised data have been published, this will not be possible anymore. ImmUniverse will provide regular updates on the study progress and results. Your individual study data will however not be shared, as the kind of data is difficult to interpret at this state of research.

Thank you for considering to participate! And remember, you can contact us at any time.

The three involved patient organisations are:

For more information on ImmUniverse please read more here and have a look at our explanatory video on the homepage.